Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Beginning Cash Balance: 2016-2025

Historic Beginning Cash Balance for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $137.3 million.

  • Akebia Therapeutics' Beginning Cash Balance rose 247.66% to $137.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.0 million, marking a year-over-year decrease of 26.89%. This contributed to the annual value of $42.9 million for FY2024, which is 53.12% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Beginning Cash Balance stood at $137.3 million, which was up 21.11% from $113.4 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Beginning Cash Balance ranged from a high of $252.8 million in Q2 2021 and a low of $34.0 million during Q4 2024.
  • Over the past 3 years, Akebia Therapeutics' median Beginning Cash Balance value was $51.9 million (recorded in 2025), while the average stood at $64.5 million.
  • In the last 5 years, Akebia Therapeutics' Beginning Cash Balance tumbled by 67.95% in 2023 and then soared by 247.66% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Beginning Cash Balance (Quarterly) stood at $207.2 million in 2021, then decreased by 29.95% to $145.1 million in 2022, then crashed by 67.95% to $46.5 million in 2023, then fell by 26.89% to $34.0 million in 2024, then surged by 247.66% to $137.3 million in 2025.
  • Its Beginning Cash Balance was $137.3 million in Q3 2025, compared to $113.4 million in Q2 2025 and $51.9 million in Q1 2025.